PMID- 31685045
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 0317-1671 (Print)
IS  - 0317-1671 (Linking)
VI  - 47
IP  - 2
DP  - 2020 Mar
TI  - Brivaracetam: First Canadian Experience in an Intractable Epilepsy Population.
PG  - 183-188
LID - 10.1017/cjn.2019.321 [doi]
AB  - OBJECTIVE: To evaluate the effectiveness and tolerability of brivaracetam (BRV) 
      in a refractory epilepsy population in an outpatient clinical setting. METHODS: 
      Retrospective medical information system review and self-report questionnaire for 
      all patients treated with BRV until the end of 2017. RESULTS: Thirty-eight 
      patients were included, 73.7% female and mean age 36.2. The mean number of 
      antiepileptic drugs (AEDs) for previous use was 8.9, and for current use was 2.5. 
      Mean seizure frequency in the last 3 months was 12 per month. At 3, 6, 12, and 15 
      months, the 50% responder rates were 36.1%, 32%, 41.2%, and 45.5%, respectively. 
      Patients took BRV for a median duration of 8.25 months, ranging from 7 days to 60 
      months. Retention rate was 75.0%, 72.0%, 59.2%, and 47.9% at 3, 6, 12, and 15 
      months, respectively. Overall, the main reasons for discontinuation were adverse 
      events (AEs) (52.3%), lack of efficacy (35.3%), or both (11.8%). The rate of 
      total AEs was 60.5% according to medical records and 85.7% according to 
      questionnaire, including mostly tiredness, psychiatric, and memory complaints. 
      Psychiatric side effects occurred in 31.6% according to medical records and 47.4% 
      according to questionnaire results, which is higher than previously reported and 
      persisted throughout the study period. CONCLUSIONS: BRV appears to be a useful 
      and safe add-on treatment, even in a very refractory group of patients. In this 
      real-life clinical setting, psychiatric AEs were found at a higher rate than 
      previously published.
FAU - Lafortune, Jeanne
AU  - Lafortune J
AD  - Department of Neurology, Centre Hospitalier Universitaire de Sherbrooke (CHUS), 
      Sherbrooke, Quebec, Canada.
FAU - Deacon, Charles
AU  - Deacon C
AD  - Department of Neurology, Centre Hospitalier Universitaire de Sherbrooke (CHUS), 
      Sherbrooke, Quebec, Canada.
FAU - Clement, Jean-Francois
AU  - Clement JF
AD  - Department of Neurology, Centre Hospitalier Universitaire de Sherbrooke (CHUS), 
      Sherbrooke, Quebec, Canada.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Can J Neurol Sci
JT  - The Canadian journal of neurological sciences. Le journal canadien des sciences 
      neurologiques
JID - 0415227
RN  - 0 (Anticonvulsants)
RN  - 0 (Pyrrolidinones)
RN  - U863JGG2IA (brivaracetam)
SB  - IM
MH  - Adult
MH  - Anger
MH  - Anticonvulsants/*therapeutic use
MH  - Anxiety/chemically induced
MH  - Canada
MH  - Depersonalization/chemically induced
MH  - Depression/chemically induced
MH  - Dizziness/chemically induced
MH  - Drug Resistant Epilepsy/*drug therapy
MH  - Drug Therapy, Combination
MH  - Emotional Regulation
MH  - Epilepsies, Partial/*drug therapy
MH  - Epilepsy, Generalized/*drug therapy
MH  - Female
MH  - Humans
MH  - Irritable Mood
MH  - Male
MH  - Memory Disorders/chemically induced
MH  - Middle Aged
MH  - Paranoid Disorders/chemically induced
MH  - Paresthesia/chemically induced
MH  - Pruritus/chemically induced
MH  - Pyrrolidinones/*therapeutic use
MH  - Retrospective Studies
MH  - Sleepiness
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Antiepileptics
OT  - Brivaracetam
OT  - Efficacy
OT  - Refractory epilepsy
OT  - Side effects
EDAT- 2019/11/07 06:00
MHDA- 2021/06/08 06:00
CRDT- 2019/11/06 06:00
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2019/11/06 06:00 [entrez]
AID - S0317167119003214 [pii]
AID - 10.1017/cjn.2019.321 [doi]
PST - ppublish
SO  - Can J Neurol Sci. 2020 Mar;47(2):183-188. doi: 10.1017/cjn.2019.321.